WO2005113786A3 - Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees a la chymase (cma1) - Google Patents

Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees a la chymase (cma1) Download PDF

Info

Publication number
WO2005113786A3
WO2005113786A3 PCT/EP2005/004897 EP2005004897W WO2005113786A3 WO 2005113786 A3 WO2005113786 A3 WO 2005113786A3 EP 2005004897 W EP2005004897 W EP 2005004897W WO 2005113786 A3 WO2005113786 A3 WO 2005113786A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
cma1
chymase
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2005/004897
Other languages
English (en)
Other versions
WO2005113786A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Priority to EP05740171A priority Critical patent/EP1766042A2/fr
Publication of WO2005113786A2 publication Critical patent/WO2005113786A2/fr
Publication of WO2005113786A3 publication Critical patent/WO2005113786A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21039—Chymase (3.4.21.39)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

L'invention concerne une CMA1 humaine qui associée aux maladies maladies cardiovasculaires, aux infections, aux maladies métaboliques, aux maladies dermatologiques, aux maladies gastroentérologiques, au cancer, à l'inflammation, aux maladies hématologiques, aux maladies respiratoires, aux maladies des muscles squelettiques, aux maladies neurologiques. Par ailleurs, 'invention concerne des analyses d'identification de composés utilisés dans le traitement ou la prévention des maladies cardiovasculaires, des infections, des maladies métaboliques, des maladies dermatologiques, des maladies gastroentérologiques, du cancer, de l'inflammation, des maladies hématologiques, des maladies respiratoires, des maladies des muscles squelettiques, des maladies neurologiques ainsi que des maladies urologiques. Par ailleurs, l'invention concerne des composés qui se lient à et/ou qui activent ou inhibent l'activité de CMA1 ainsi que des compositions pharmaceutiques qui contiennent ces composés.
PCT/EP2005/004897 2004-05-21 2005-05-06 Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees a la chymase (cma1) WO2005113786A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05740171A EP1766042A2 (fr) 2004-05-21 2005-05-06 Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees a la chymase (cma1)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04012033 2004-05-21
EP04012033.9 2004-05-21

Publications (2)

Publication Number Publication Date
WO2005113786A2 WO2005113786A2 (fr) 2005-12-01
WO2005113786A3 true WO2005113786A3 (fr) 2006-02-09

Family

ID=34966986

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/004897 WO2005113786A2 (fr) 2004-05-21 2005-05-06 Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees a la chymase (cma1)

Country Status (2)

Country Link
EP (1) EP1766042A2 (fr)
WO (1) WO2005113786A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080084806A (ko) * 2005-11-10 2008-09-19 시너젠즈 바이오사이언스 리미티드 심혈관 기능 및 질환의 평가를 위한 방법 및 조성물
AR077049A1 (es) * 2009-06-11 2011-07-27 Otsuka Pharma Co Ltd Aptamero contra quimasa y su uso
EP2524927A1 (fr) * 2011-05-20 2012-11-21 Covagen AG Nouveaux composés de liaison de chymase et utilisations médicales associées

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567602A (en) * 1992-08-12 1996-10-22 Arris Pharmaceutical Corporation Recombinant production of chymase
JPH10245384A (ja) * 1997-03-05 1998-09-14 Teijin Ltd 新規トリアジンスルホン誘導体
JP2001031636A (ja) * 1999-05-18 2001-02-06 Senju Pharmaceut Co Ltd α−ケトアミド誘導体およびその医薬用途
WO2002068579A2 (fr) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits tels que des dosages d'acides nucleiques comprenant une majorite d'exons ou de transcrits humains, destines a detecter l'expression et pouvant avoir d'autres applications
JP2002300886A (ja) * 2001-04-06 2002-10-15 Katakura Industries Co Ltd 安定な組換え型ヒトキマーゼおよびその製造法並びにこれを用いるスクリーニング方法
US6607879B1 (en) * 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
JP2003235556A (ja) * 2002-02-15 2003-08-26 Katakura Industries Co Ltd 抗ヒトキマーゼモノクローナル抗体およびそれらの利用
WO2004063340A2 (fr) * 2003-01-13 2004-07-29 Millennium Pharmaceuticals, Inc. Methodes et compositions pour traiter les maladies cardio-vasculaires au moyen de genes 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612,

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567602A (en) * 1992-08-12 1996-10-22 Arris Pharmaceutical Corporation Recombinant production of chymase
JPH10245384A (ja) * 1997-03-05 1998-09-14 Teijin Ltd 新規トリアジンスルホン誘導体
US6607879B1 (en) * 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
JP2001031636A (ja) * 1999-05-18 2001-02-06 Senju Pharmaceut Co Ltd α−ケトアミド誘導体およびその医薬用途
WO2002068579A2 (fr) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits tels que des dosages d'acides nucleiques comprenant une majorite d'exons ou de transcrits humains, destines a detecter l'expression et pouvant avoir d'autres applications
JP2002300886A (ja) * 2001-04-06 2002-10-15 Katakura Industries Co Ltd 安定な組換え型ヒトキマーゼおよびその製造法並びにこれを用いるスクリーニング方法
JP2003235556A (ja) * 2002-02-15 2003-08-26 Katakura Industries Co Ltd 抗ヒトキマーゼモノクローナル抗体およびそれらの利用
WO2004063340A2 (fr) * 2003-01-13 2004-07-29 Millennium Pharmaceuticals, Inc. Methodes et compositions pour traiter les maladies cardio-vasculaires au moyen de genes 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612,

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAUGHEY G H ET AL: "STRUCTURE CHROMOSOMAL ASSIGNMENT AND DEDUCED AMINO ACID SEQUENCE OF A HUMAN GENE FOR MAST CELL CHYMASE", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 266, no. 20, 1991, pages 12956 - 12963, XP002164694, ISSN: 0021-9258 *
JIN DENAN ET AL: "Chymase-derived angiotensin II and arrhythmias after myocardial infarction.", FOLIA PHARMACOLOGICA JAPONICA, vol. 124, no. 2, August 2004 (2004-08-01), pages 77 - 82, XP008050647, ISSN: 0015-5691 *
LIAO, Y. & HUSAIN, A.: "THE CHYMASE-ANGIOTENSIN SYSTEM IN HUMANS: BIOCHEMISTRY, THE CHYMASE-ANGIOTENSIN SYSTEM IN HUMANS: BIOCHEMISTRY, MOLECULAR BIOLOGY AND POTENTIAL ROLE IN CARDIOVASCULAR DISEASES", CANADIAN JOURNAL OF CARDIOLOGY, vol. 11, no. F, 1 August 1995 (1995-08-01), pages 13F - 19F, XP000565787 *
NISHIMURA HIKARU ET AL: "Angiotensin I converting enzyme and chymase in cardiovascular tissues", KIDNEY INTERNATIONAL SUPPLEMENT, vol. 0, no. 55, 1996, pages S18 - S23, XP008050706, ISSN: 0098-6577 *
NIWATA S ET AL: "substituted 3-(Phenylsulfonyl)-1-phenylimidazolidine-2,4-dione derivatives as novel nonpeptide inhibitors of human heart chymase", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 40, no. 14, 1997, pages 2156 - 2163, XP002122640, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
EP1766042A2 (fr) 2007-03-28
WO2005113786A2 (fr) 2005-12-01

Similar Documents

Publication Publication Date Title
WO2006027147A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur d'adrenomedulline (amdr)
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2005106012A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1)
WO2006010517A3 (fr) Diagnostic et traitement therapeutique des maladies associees a la proteine d'activation des fibroblastes (fap)
WO2005100990A3 (fr) Methodes diagnostiques et therapeutiques pour des maladies associees au purinocepteur 2 de type y (p2y2)
WO2005103684A3 (fr) Diagnostics et methodes therapeutiqeus pour des maladies associees au recepteur 1 de la chimiokine cx3c
WO2005113786A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees a la chymase (cma1)
WO2006021343A3 (fr) Diagnostic et therapie de maladies associees au recepteur 3a de la 5-hydroxytryptamine (5-ht3a)
WO2006010514A3 (fr) Diagnostic et traitement therapeutique des maladies associees a la proteine kinase kinase 5 activee par les mitogenes (map2k5) a double specificite
WO2005076007A3 (fr) Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12)
WO2005093091A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26)
WO2006013013A3 (fr) Agents pour le diagnostic et le traitement de maladies associees a la proteine protectrice pour la beta-galactosidase (ppgb)
WO2005106486A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 3 (dpp3)
WO2005073729A3 (fr) Diagnostic et traitement de maladies associees au recepteur p2y11 couple a une proteine g (p2y11)
WO2006040047A3 (fr) Diagnostics et therapeutiques pour des maladies associees a la kinase citron agissant sur rho/rac
WO2006005470A3 (fr) Agents diagnostiques et therapeutiques pour des maladies associees au recepteur couple a la proteine g lie au mas (mrge)
WO2005085469A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees a la proteine kinase 1 associee a rho (rock1)
WO2006013014A3 (fr) Diagnostics et therapeutiques pour maladies liees a une proteine similaire a un antigene membranaire specifique de la prostate (psmal)
WO2005101011A3 (fr) Agents diagnostiques therapeutiques pour des maladies associees a lxr-alpha (lxra)
WO2005075983A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a un recepteur nucleaire humain nr4a3 (nr4a3)
WO2006013015A3 (fr) Diagnostics et therapeutique pour maladies liees a la marapsine (mpn)
WO2006010497A3 (fr) Diagnostics et therapeutiques pour des maladies associees a choline kinase (chk)
WO2006013012A3 (fr) Diagnostics et therapeutique pour maladies liees a la napsine 1 (nap1)
WO2006010515A3 (fr) Diagnostic et traitement therapeutique des maladies associees a la 5-hydroxytryptamine 2a (5ht2a)
WO2005101009A3 (fr) Outils diagnostiques et therapeutiques pour maladies associees au recepteur 2 de tachykinine (tacr2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005740171

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005740171

Country of ref document: EP